AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32414386 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HA device)
Number of subjects: 18
Study 33772971 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD+ smokers
Number of subjects: 1854
Study 33772971 — intervention group
Group type: COMPARATOR
Intervention: MDD‐ smokers
Number of subjects: 1854
Study 33060837 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network (CNN) based computer-aided detection (CAD) system using eDenseYOLO.
Number of subjects: 9792
Study 33594386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride film (APL‐130277, Kynmobi) administered up to 5 times a day
Number of subjects: 0
Study 32866927 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 2500
Study 32866927 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 2500
Study 35316458 — intervention group
Group type: EXPERIMENTAL
Intervention: Facing History and Ourselves intervention group
Number of subjects: 694
Study 35316458 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 694
Study 32187315 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from nurses in addition to outpatient consultations
Number of subjects: 29
Study 32187315 — intervention group
Group type: COMPARATOR
Intervention: Outpatient consultations only
Number of subjects: 29
Study 32187315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 35850436 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithothamnion (100 mg/kg bw PO BID) for 7 days before oligofructose intake (10 g/kg PO)
Number of subjects: 12
Study 35850436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 12
Study 33112408 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 Units at 12-week intervals
Number of subjects: 465
Study 33112408 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA in extension cycles 1, 2, and 3
Number of subjects: 465
Study 33112408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 33112408 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 465
Study 35872954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall oral care (observation group)
Number of subjects: 70
Study 35872954 — intervention group
Group type: COMPARATOR
Intervention: Basic oral care (control group)
Number of subjects: 70
Study 33861701 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel automatic initialization using a neural network trained to detect anatomical landmarks on simulated X-rays.
Number of subjects: 0
Study 32903140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 tumors
Number of subjects: 317
Study 32903140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 tumors in patients < 18 months
Number of subjects: 317
Study 32903140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 tumors in patients ≥ 18 months
Number of subjects: 317
Study 32903140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1p loss in patients < 18 months
Number of subjects: 317
Study 32903140 — intervention group
Group type: EXPERIMENTAL
Intervention: 11q loss in patients ≥ 18 months
Number of subjects: 317
Study 34692725 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (wild type treated group)
Number of subjects: 92
Study 34692725 — intervention group
Group type: COMPARATOR
Intervention: Control group (NAFLD wild type controls)
Number of subjects: 92
Study 34692725 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (mutated treated group)
Number of subjects: 92
Study 33925277 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight-interval training (CWIT) for 12 weeks, 2 sessions of 40 minutes per week
Number of subjects: 27
Study 33925277 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued sedentary behavior)
Number of subjects: 27
Study 34181714 — intervention group
Group type: EXPERIMENTAL
Intervention: cPass neutralization antibody assay
Number of subjects: 316
Study 34181714 — intervention group
Group type: COMPARATOR
Intervention: Commercial serology assays (Abbott, Euroimmun, Siemens)
Number of subjects: 316
Study 34181714 — intervention group
Group type: COMPARATOR
Intervention: Commercial serology assays (Abbott)
Number of subjects: 316
Study 34181714 — intervention group
Group type: COMPARATOR
Intervention: Commercial serology assays (Euroimmun)
Number of subjects: 316
Study 34181714 — intervention group
Group type: COMPARATOR
Intervention: Commercial serology assays (Siemens)
Number of subjects: 316
Study 32118260 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth system
Number of subjects: 115
Study 32118260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 32118260 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported daily abstinence
Number of subjects: 115
Study 32118260 — intervention group
Group type: EXPERIMENTAL
Intervention: 12S-ABS and HC-ABS patients
Number of subjects: 115
Study 35962654 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual breastmilk expression (ME) using Marmet technique
Number of subjects: 170
Study 35962654 — intervention group
Group type: COMPARATOR
Intervention: Breast pump milk expression (PE) using pigeon manual breast pump
Number of subjects: 170
Study 33836800 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemoRadiation and Immunotherapy (CRIO) with durvalumab (anti-PD-L1 checkpoint inhibitor)
Number of subjects: 15
Study 35469779 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular (ATVV) intervention
Number of subjects: 102
Study 35469779 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular with odor from a baby lotion (ATVVO)
Number of subjects: 102
Study 35469779 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) group
Number of subjects: 102
Study 33342580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention in addition to usual care
Number of subjects: 224
Study 33342580 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study 33093598 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 11
Study 33093598 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-entacapone-carbidopa intestinal gel (LECIG)
Number of subjects: 11
Study 33093598 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone with LCIG
Number of subjects: 11
Study 35916398 — intervention group
Group type: EXPERIMENTAL
Intervention: Homebound Elderly People Psychotherapeutic Intervention (HEPPI)
Number of subjects: 51
Study 35916398 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 51
Study 33989106 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (20 µg) of recombinant hepatitis B vaccine
Number of subjects: 284
Study 33989106 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (60 µg) of recombinant hepatitis B vaccine
Number of subjects: 284
Study 33989106 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 284
Study 33989106 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAID analysis
Number of subjects: 284
Study 32951731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Gamma Globulin (IVIG)
Number of subjects: 0
Study 33612830 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 66
Study 33612830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32441833 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (5 g)
Number of subjects: 120
Study 32441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg)
Number of subjects: 120
Study 32441833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined L-arginine (5 g) with tadalafil (5 mg)
Number of subjects: 120
Study 32441833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33646930 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 382
Study 33646930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 32808018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold marker matching in the surrounding tissue of the prostate
Number of subjects: 38
Study 32808018 — intervention group
Group type: COMPARATOR
Intervention: Bone matching
Number of subjects: 38
Study 32808018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold marker matching
Number of subjects: 38
Study 36450546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Remote Ischemic Conditioning (CRIC)
Number of subjects: 61
Study 36450546 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 33131199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 53
Study 33131199 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 53
Study 33184642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 37
Study 33184642 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3
Number of subjects: 37
Study 33184642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 33405453 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous dentin graft (Group D)
Number of subjects: 9
Study 33405453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of PRF and autogenous dentin graft (Group DP)
Number of subjects: 9
Study 33405453 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 9
Study 32346743 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy with motor imagery (MI) principles
Number of subjects: 24
Study 32346743 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 24
Study 35312850 — intervention group
Group type: EXPERIMENTAL
Intervention: EA model
Number of subjects: 0
Study 35312850 — intervention group
Group type: COMPARATOR
Intervention: DB model
Number of subjects: 0
Study 34110478 — intervention group
Group type: EXPERIMENTAL
Intervention: HM laparoscopic trainer
Number of subjects: 26
Study 34110478 — intervention group
Group type: COMPARATOR
Intervention: KS trainer
Number of subjects: 26
Study 32826836 — intervention group
Group type: EXPERIMENTAL
Intervention: Table position (T)
Number of subjects: 52
Study 32826836 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm position with head close to provider's elbow (P)
Number of subjects: 52
Study 32826836 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm position with head close to provider's palm (D)
Number of subjects: 52
Study 34564686 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 2mg/5ml
Number of subjects: 32
Study 34564686 — intervention group
Group type: COMPARATOR
Intervention: Topical cyclosporine 100mg/ml
Number of subjects: 32
Study 35368605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 193
Study 35368605 — intervention group
Group type: COMPARATOR
Intervention: Placebo nonresponders
Number of subjects: 193
Study 35368605 — intervention group
Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 193
Study 35368605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 193
Study 37821187 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stent
Number of subjects: 880
Study 37821187 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880
Study 37821187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 880
Study 32462277 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide mixed with lidocaine HCl
Number of subjects: 60
Study 32462277 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide mixed with saline
Number of subjects: 60
Study 32353115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin (70 μg/hour for 2.5 hours)
Number of subjects: 0
Study 32353115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study 35943903 — intervention group
Group type: EXPERIMENTAL
Intervention: Online peer support intervention based on acceptance and commitment therapy
Number of subjects: 107
Study 35943903 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 107
Study 36445895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 101
Study 36445895 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 101
Study 36445895 — intervention group
Group type: COMPARATOR
Intervention: Assessment-Only (AO)
Number of subjects: 101
Study 34481070 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated smoking cessation pharmacotherapy recommendation algorithm integrated into HIV primary care
Number of subjects: 600
Study 34481070 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care condition
Number of subjects: 600
Study 35258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 1 contractions per minute (cpm)
Number of subjects: 49
Study 35258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 6 contractions per minute (cpm)
Number of subjects: 49
Study 35258750 — intervention group
Group type: COMPARATOR
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 12 contractions per minute (cpm)
Number of subjects: 49
Study 35258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Skeletal Muscle Tension (RSMT) at 1 and 6 cpm
Number of subjects: 49
Study 32073111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionically crosslinked polyisoprene elastomers with varying molecular weight and carboxy group content
Number of subjects: 0
Study 32073111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher molecular weight PI elastomers
Number of subjects: 0
Study 36332361 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with paracetamol
Number of subjects: 186
Study 36332361 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (ASAQ)
Number of subjects: 186
Study 36332361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine‐artesunate (PA)
Number of subjects: 186
Study 36332361 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir plus nitazoxanide (FPV + NTZ)
Number of subjects: 186
Study 36332361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir‐daclatasvir (SOF‐DCV)
Number of subjects: 186
Study 33176071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 71
Study 33176071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 71
Study 33176071 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 71
Study 35527651 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimunex® gocce (food supplement) given daily for 4 months
Number of subjects: 298
Study 35527651 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for respiratory infections (Control group)
Number of subjects: 298
Study 35527651 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimunex® gocce (food supplement)
Number of subjects: 298
Study 32134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acting with awareness (AWA)
Number of subjects: 210
Study 32134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 210
Study 32134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 210
Study 32134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect through AWA
Number of subjects: 210
Study 32134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect through suppression
Number of subjects: 210
Study 32740442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 642
Study 32621557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) levels above 7%
Number of subjects: 14656
Study 32621557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) levels below 7%
Number of subjects: 14656
Study 35938327 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged acupuncture
Number of subjects: 60
Study 35938327 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 35938327 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 60
Study 33658030 — intervention group
Group type: EXPERIMENTAL
Intervention: Malocclusion severity
Number of subjects: 255
Study 35410930 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable catheters replaced every 2 weeks and cleaning solution replaced every 24 hours
Number of subjects: 456
Study 35410930 — intervention group
Group type: COMPARATOR
Intervention: Single use catheters
Number of subjects: 456
Study 35410930 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable catheters
Number of subjects: 456
Study 33843667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase 2,000 fibrinolytic units
Number of subjects: 265
Study 33843667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily patient contact
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct contact with COVID-19 patients
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in COVID-19 units
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact in patient rooms
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact in reception areas
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contact with suspected or proven SARS-CoV-2 infection
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contact with proven SARS-CoV-2 infection
Number of subjects: 1874
Study 34226231 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent mask use on public transportation
Number of subjects: 1874
Study 35789639 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 144
Study 35789639 — intervention group
Group type: COMPARATOR
Intervention: Dynamic neuromuscular stabilization (DNS) exercise
Number of subjects: 144
Study 33743737 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose supplementation
Number of subjects: 9
Study 32856272 — intervention group
Group type: EXPERIMENTAL
Intervention: Single RAS blocker therapy
Number of subjects: 112
Study 32856272 — intervention group
Group type: COMPARATOR
Intervention: Dual RAS blocker therapy
Number of subjects: 112
Study 32856272 — intervention group
Group type: COMPARATOR
Intervention: Both single and dual RAS blocker therapy
Number of subjects: 112
Study 70711958 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginaid formula (arginine enhanced diet, ISOCAL<sup>R</sup>) - 3 packs/day for 2 days before surgery and on postoperative days 4 to 9
Number of subjects: 330
Study 70711958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Arginaid)
Number of subjects: 330
Study 70711958 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginaid formula (arginine enhanced diet, ISOCAL<sup>R</sup>)
Number of subjects: 330
Study 36129749 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (Mobile for Mothers)
Number of subjects: 740
Study 34519400 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA) therapy
Number of subjects: 0
Study 32118792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 1 week (t=1)
Number of subjects: 15
Study 32118792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 4 weeks (t=4)
Number of subjects: 15
Study 32118792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 8 weeks (t=8)
Number of subjects: 15
Study 32118792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 300g applied for 12 weeks (t=12)
Number of subjects: 15
Study 32118792 — intervention group
Group type: COMPARATOR
Intervention: Control group (t=0) - teeth extracted without orthodontic treatment
Number of subjects: 15
Study 35195015 — intervention group
Group type: EXPERIMENTAL
Intervention: VERB intervention (educational materials, brief motivational interview, pillbox, primary care engagement letter, pharmacy resources, and 45 days of informational and reminder text messages)
Number of subjects: 206
Study 35195015 — intervention group
Group type: EXPERIMENTAL
Intervention: VERB intervention
Number of subjects: 206
Study 35195015 — intervention group
Group type: COMPARATOR
Intervention: Education arm (received a hypertension pamphlet)
Number of subjects: 206
Study 35195015 — intervention group
Group type: COMPARATOR
Intervention: Education arm
Number of subjects: 206
Study 34106135 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing significance level from α = 0.05 to α = 0.005 in cross-sectional studies
Number of subjects: 0
Study 34106135 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing significance level from α = 0.05 to α = 0.005 in comparative studies
Number of subjects: 0
Study 34106135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost implications of changing significance level
Number of subjects: 0
Study 32758278 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34240265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with nutritional supplementation (Fortifit)
Number of subjects: 95
Study 34240265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training without nutritional supplementation
Number of subjects: 95
Study 34240265 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (control for socialisation)
Number of subjects: 95